切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2016, Vol. 05 ›› Issue (05) : 218 -222. doi: 10.3877/cma.j.issn.2095-3216.2016.05.007

所属专题: 文献

论著

伴有新月体形成的原发性IgA肾病的临床与病理特点及预后分析
南蕾1, 王慧1, 贾妮亚1, 王彩丽1,(), 张艳辉1   
  1. 1. 014010 包头医学院第一附属医院肾内科
  • 收稿日期:2016-04-21 出版日期:2016-10-28
  • 通信作者: 王彩丽

Analysis of clinical and pathological features and prognosis for primary IgA nephropathy with glomerular crescents formation

Lei Nan1, Hui Wang1, Niya Jia1, Caili Wang1,(), Yanhui Zhang1   

  1. 1. Department of Nephrology, First Hospital Affiliated to Baotou Medical College, Baotou 014010, China
  • Received:2016-04-21 Published:2016-10-28
  • Corresponding author: Caili Wang
  • About author:
    Corresponding author: Wang Caili, Email:
引用本文:

南蕾, 王慧, 贾妮亚, 王彩丽, 张艳辉. 伴有新月体形成的原发性IgA肾病的临床与病理特点及预后分析[J/OL]. 中华肾病研究电子杂志, 2016, 05(05): 218-222.

Lei Nan, Hui Wang, Niya Jia, Caili Wang, Yanhui Zhang. Analysis of clinical and pathological features and prognosis for primary IgA nephropathy with glomerular crescents formation[J/OL]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2016, 05(05): 218-222.

目的

观察伴有新月体形成的原发性IgA肾病的临床、病理特点,分析其对激素及环磷酰胺治疗的反应。

方法

收集包头医学院第一附属医院1997年8月至2015年04月收治的80例经肾活检确诊为原发性IgA肾病并伴新月体形成的患者,并依据新月体累及的肾小球比例进行分组,新月体占受累肾小球比例≥50% (A组) 24例;新月体累及的肾小球比例<50%(B组) 56例。肾小球系膜增生、肾小管间质病变采用R.Katafuchi标准积分量化。对两组的临床及病理特点进行比较。治疗方案:将A、B两组再分为单纯糖皮质激素(激素)治疗组,激素+环磷酰胺治疗组,分别比较不同治疗方案对各组的疗效。A、B组各有24例患者接受了随访。应用SPSS软件进行统计学分析。

结果

①临床方面:32例(40%)患者有镜下血尿+蛋白尿,76例(95%)患者尿蛋白≥2 g/24 h,32例(40%)患者有肉眼血尿;水肿、高血压、肾功能异常者超过半数。A组尿蛋白量及血清肌酐明显高于B组(t=1.890,t=2.570; P<0.05),血清白蛋白及肾小球滤过率明显低于B组(t=2.681, t=3.014;P<0.05)。②病理方面:所有受累肾小球的新月体面积百分比为5.92%~88.9%,其中A组为52.6%~88.9%, B组为5.92%~48.9%;与B组比较A组肾小管间质损害更严重,两组比较差异有统计学(P<0.05)。③治疗情况:A组及B组经激素或激素+环磷酰胺治疗后,尿蛋白定量均明显减少(P<0.05) ;单纯激素治疗后A组血清肌酐较治疗前有明显下降(t=3.243,P<0.05)。随访2~4年时,A组8例患者出现血清肌酐升高,达透析指征,1例死亡;B组2例患者出现血清肌酐升高(1例原有轻度升高,1例新出现血清肌酐升高)。

结论

IgA肾病患者随着新月体占受累肾小球比例的增加,肾小管间质病理损害及临床表现亦逐渐加重且预后不佳;激素治疗可减少伴有大新月体形成的原发性IgA肾病的蛋白尿并有可能改善其肾功能。

Objective

To observe the clinical and pathological features of primary IgA nephropathy with glomerular crescents formation, and to analyze its response to treatment with corticosteroids and cyclophosphamide.

Methods

From August 1997 to April 2015 in the First Hospital Affiliated to Baotou Medical College, a total of 80 patients of primary IgA nephropathy with crescents formation confirmed by renal biopsy were divided into group A (area ratio of crescents to involved glomeruli ≥50%) (n=28) and group B (area ratio of crescents to involved glomeruli <50%) (n=52). Glomerular mesangial proliferation and renal tubular interstitial lesions were quantified with scores by the Katafuchi criteria. And the clinical and pathological features were also compared. Treatment plan: both group A and group B were divided into corticosteroids subgroup, and corticosteroids plus cyclophosphamide subgroup. Follow-up was made in group A and group B with 24 cases each. And statistical analysis was made with the SPSS software.

Results

Microscopic hematuria and proteinuria occurred in 32 patients (40%); 76 patients (95%) had proteinuria no less than 2 g/24 h; 32 patients (40%) had macrohematuria; edema, hypertension, and abnormal kidney function were found in more than 50% of the patients. In group A, proteinuria was significantly higher than in group B (t=1.890, P<0.05), while serum albumin and glomerular filtration rate were significantly lower than in group B (t=2.681, t=3.014; P<0.05). The area percentage of the crescents over the affected glomeruli was 5.92%-88.9% totally, 52.6%-88.9% in group A, and 5.92%- 48.9% in group B. Compared with group B, group A had more serious renal tubular damage (P<0.05). After treatment with corticosteroids plus cyclophosphamide, quantitative proteinuria was significantly reduced in both group A and group B (χ2=4.010, χ2=4.902, P<0.05). After the corticosteroids therapy, the reduction of serum creatinine was more significant in group A than in group B (χ2=5.882, P<0.05). After followed-up for 2-4 years, 8 cases had elevated serum creatinine that met the dialysis indications, and 1 case died in group A; 2 cases had increased serum creatinine (one case with slight baseline elevation, and the other with new elevation of serum creatinine).

Conclusions

In the patients with IgA nephropathy, with increase of the proportion of crescents area over the affected glomeruli, the renal tubulointerstitial pathological damage and clinical manifestation gradually aggravated with poor prognosis. In the primary IgA nephropathy with big crescents formation, the corticosteroids therapy could decrease proteinuria and might be able to improve the renal function.

表1 两组患者临床及实验室资料
表2 两组患者肾小球、肾小管间质病变的比较(Katafuchi积分)
表3 A、B组患者进一步分为单纯激素治疗组及激素加环磷酰胺治疗组治疗前后疗效对照(±s)
1
余英豪,郑智勇.肾穿刺活检病理诊断彩色图谱[M].福州:福建科学技术出版社,2008:145-158.
2
陈香美,谢院生.重视延缓IgA肾病进展的基础和临床研究[J].中华肾脏病杂志,2004,20(4):235-237.
3
Donadio JV, Grande JP. IgA nephropathy [J]. N Engl J Med, 2002, 347(10):738-748.
4
Lai AS, Lai KN. Molecular basis of IgA nephropathy [J]. Curr Mol Med, 2005, 5(5):475-478.
5
Barratt J, Feehally J, Smith AC. Pathogenesis of IgA nephropathy [J]. Semin Nephrol, 2004, 24(3):197-217.
6
Coppor R, Carrran D, Roberts Ian SD. The new oxford clinico-pathological classification of IgA nephropathy [J]. Prilozi, 2010, 31(1):241-248.
7
Tumilin JA, Lohavichan V, Hennigar R. Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide [J]. Nehhrol Dial Transplant, 2003, 18(7):1321-1329.
8
Daniel L, Saingra Y, Giorgi R, et al. Tubular lesions determine prognosis of IgA nephropathy [J]. Am J Kidney Dis, 2000, 35(1):13-20.
9
沈世忠,郭冰云,吴建平,等.伴和不伴新月体形成IgA肾病的临床与病理研究 [J].中国中西医结合肾病杂志,2008,9(9):795-796.
10
宛霞,李劲高,白婕,等.伴有新月体形成的IgA肾病的临床特征及预后[J].南方医科大学学报,2007,27(3):3366-339.
11
杨念生,武庆庆,杜勇,等.影响IgA肾病预后的危险因素分析[J].中华内科杂志,2005,44(8):597-600.
12
郑爱萍,熊子波,张帆,等.伴新月体形成的青壮年原发性IgA肾病临床病理特征分析[J]. 实用临床医学,2012, 13(6) :21-24.
13
姚勇,刘景城,肖慧捷,等. 伴有新月体形成的原发性IgA肾病的临床与病理分析[J]. 中华儿科杂志,2004, 42(6):412-416.
14
鲍浩,唐政,俞雨生,等.霉酚酸酯与环磷酰胺治疗新月体型IgA肾病的疗效比较[J].肾脏病与透析移植杂志,2007,16(5):41-46.
15
Floege J, Feehally J. IgA nephropathy: recent developments [J]. J Am Soc Nephrol, 2000, 11(12):2395-2403.
[1] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 778-784.
[2] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[3] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[4] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[5] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[6] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[7] 刘柏隆, 周祥福. 压力性尿失禁阶梯治疗的项目介绍[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 125-125.
[8] 刘柏隆. 女性压力性尿失禁阶梯治疗之手术治疗方案选择[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 126-126.
[9] 中华医学会器官移植学分会. 肝移植术后缺血性胆道病变诊断与治疗中国实践指南[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 739-748.
[10] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[11] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[12] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[13] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
[14] 张平骥, 徐钰, 李天水, 庞文翼, 符师宁, 张梦圆. 重症患者镇静治疗现状及期望的调查研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 562-567.
[15] 王昌前, 林婷婷, 宁雨露, 王颖杰, 谭文勇. 光免疫治疗在肿瘤领域的临床应用新进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 575-583.
阅读次数
全文


摘要